Rainbow Children's Medicare Limited
Financial trend (93/100) does the heavy lifting; valuation (14/100) is the drag.
ExpensiveOvervaluedStocksWizard rates Rainbow Children's Medicare Limited a Hold, scoring 45/100 on our blended model. On 52.4x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 5% below its 52-week high of ₹1,582.88 and 36% above the low of ₹1,101.21. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹1,599.62 implies about 7% upside across 13 analysts. It clears 9 of 13 investability checks, with durability 75, valuation 25 and momentum 86 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹859.76.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-5.44% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 17.9%
- Fail: Low debt (D/E < 0.5): 0.54x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 24%
- Pass: Earnings growing: 39%
- Pass: Net margin ≥ 10%: 16.3%
- Pass: Current ratio > 1.5: 3.59
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 9.16
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter53.8%
- Institutions36.9%
- Public & other9.3%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Healthy profit margin (16.3%).
- Financially solid — Altman Z 9.16.
Opportunities
- Earnings growing (39% YoY).
- Revenue growing (24% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~28% above our estimated fair value.
About Rainbow Children's Medicare Limited
Rainbow Children's Medicare operates a hospital chain in India focused on pediatric, obstetric, and gynecological services. Its Rainbow Children's Hospital brand provides newborn and pediatric intensive care, multi-specialty pediatric services, and quaternary care including multi-organ transplantation. The company delivers medical and healthcare services primarily to children and women.
Rainbow Children's Medicare Limited — frequently asked questions
Is Rainbow Children's Medicare Limited a buy, hold or sell?
StocksWizard currently rates Rainbow Children's Medicare Limited (RAINBOW) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Rainbow Children's Medicare Limited's fair value?
Our blended DCF and relative-valuation model estimates Rainbow Children's Medicare Limited's fair value at about ₹1,074.71, versus a current price of ₹1,496.7 — roughly 28% downside. On that basis the stock looks overvalued by 28%.
Is Rainbow Children's Medicare Limited financially healthy?
Rainbow Children's Medicare Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Rainbow Children's Medicare Limited's share price performed?
Rainbow Children's Medicare Limited is up 20% over three months, and last traded at ₹1,496.7. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.